Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Aypar, Eda; Izzettin, Fikret; Aki, Sahika; SANCAR, MESUT; YEGİN, ZEYNEP; Turkoz-Sucak, Gulsan

doi:10.1177/1078155217697486

Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib

Copy For Citation

Aypar E., Izzettin F. V., Aki S. Z., SANCAR M., YEGİN Z. A., Turkoz-Sucak G.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.24, no.4, pp.281-289, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 24 Issue: 4
Publication Date: 2018
Doi Number: 10.1177/1078155217697486
Journal Name: JOURNAL OF ONCOLOGY PHARMACY PRACTICE
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.281-289
Gazi University Affiliated: Yes

Abstract

Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.